Gene expression profiling: Will it complement or replace immunophenotyping?

Best Practice and Research: Clinical Haematology

Volumn 16, Issue 4, 2003, Pages 645-652

  Ferrando, Adolfo A ^a   Look, A Thomas ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Classification of leukaemias and lymphomas; DNA microarrays; Flow cytometry; Immunophenotyping; Prognostic evaluation

Indexed keywords

MEMBRANE ANTIGEN; RNA;

CANCER CELL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER THERAPY; CELL CLONE; DIAGNOSTIC ACCURACY; DNA MICROARRAY; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOME; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA; LEUKEMIA CELL; LYMPHOMA; LYMPHOMA CELL; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; PATHOLOGIST; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; TREATMENT PLANNING; DIAGNOSTIC PROCEDURE; INTERMETHOD COMPARISON;

EID: 0242521473     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(03)00069-0     Document Type: Article

References (18)

1. van Gelder RN, von Zastrow ME, Yool A et al. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proceedings of the National Academy of Sciences of the USA 1990; 87: 1663-1667.
2. Wang E, Miller LD, Ohnmacht GA et al. High-fidelty mRNA amplification for gene profiling. Nature Biotechnology 2000; 4: 457-459.
3. Baugh LR, Hill AA, Brown EL & Hunter CP. Quantitative analysis of mRNA amplification by in vitro transcription. Nucleic Acids Research 2001; 29: E29.
4. Xiang CC, Chen M, Kozhich OA et al. Probe generation directly from small numbers of cells for DNA microarray studies. BioTechniques 2003; 34: 386-393.
5. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
6. Jaffe ES, Harris NL, Stein H & Vardiman JWE. Pathology and Genetics of Tumors of Haematopietic and Lymphoid Tissues. IARC Press, Lyon, 2001.
7. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-537.
8. Yeoh EJ, Ross ME, Shurtleff SA et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1: 133-143.
9. Armstrong SA, Staunton JE, Silverman LB et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genetics 2002; 30: 41-47.
10. Ferrando A, Armstrong SA, Neuberg DS et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 2003; 102: 262-268.
11. Rosenwald A, Alizadeh AA, Widhopf G et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. Journal of Experimental Medicine 2001; 194: 1639-1647.
12. Hofmann WK, de Vos S, Elashoff D et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 2002; 359: 481-486.
13. Rosenwald A, Wright G, Wiestner A et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185-197.
14. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
15. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New England Journal of Medicine 2002; 346: 1937-1947.
16. Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Medicine 2002; 8: 68-74.
17. Davis RE, Brown KD, Siebenlist U & Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. Journal of Experimental Medicine 2001; 194: 1861-1874.
18. Armstrong SA, Kung AL, Mabon ME et al. Inhibition of FLT3 in MLL Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003; 3: 173-183.